The PBS subsidises pasireotide and pegvisomant for patients with acromegaly.

Pasireotide and pegvisomant can be subsidised through the PBS under section 100 of the National Health Act 1953 for patients with acromegaly.

Section 100 arrangements

These items are only available to a patient who is attending:

  • an approved private hospital
  • a public participating hospital, or
  • a public hospital

and is a

  • day admitted patient
  • non-admitted patient, or
  • patient on discharge

These items are not available as a PBS benefit for in-patients of a hospital. The hospital provider name and number must be included on the application form.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing pasireotide and pegvisomant.


Initial treatment

Make all initial applications for authority approval to prescribe pasireotide and pegvisomant for the treatment of acromegaly in writing and:

All applications for pasireotide must include a completed:

All applications for pegvisomant must include a completed:

Initial grandfather treatment - pegvisomant

For patients who received non PBS subsidised pegvisomant treatment for acromegaly before 1 September 2017, make all initial grandfather applications in writing and:

All applications must include a completed:

A patient may qualify for PBS subsidised pegvisomant under the grandfather restriction once only.

Continuing treatment

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 22 February 2019

Was this page useful?
Why not?

Thank you for your feedback.